SHH and cancer: In addition, an actively recruiting randomized controlled phase II trial (PersoMed-I, NCT04402073) by the European Organisation for Research and Treatment of Cancer aims to assess the efficacy of sonidegib with reduced-dose radiotherapy in post-pubertal patients with SHH-activated medulloblastomas.